Atropine micro-formulation - Eyenovia

Drug Profile

Atropine micro-formulation - Eyenovia

Alternative Names: MicroPine

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eyenovia
  • Class Alkaloids; Antidotes; Cardiovascular therapies; Eye disorder therapies; Small molecules; Tropanes
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Myopia

Most Recent Events

  • 05 Jun 2018 Eyenovia receives patent allowances for micro-therapeutic ophthalmic delivery system in USA
  • 27 Mar 2018 Chemical structure information added
  • 21 Feb 2018 Eyenovia plans a pivotal phase III trial for Myopia in USA (Topical) in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top